Affiliation:
1. Ankara Eğitim ve Araştırma Hastanesi
Abstract
Aim: Botulinum toxin type A (BTX-A) treatment for facial rejuvenation has
been started to used widely and become the most common aesthetic procedure. The aim in
this study to evaluate the patients features and outcomes who had Onabotulinumtoxin A.
Material and Method: The data of the BTX-A patient’s gender, age, occupation, history of cosmetic
procedures, history of disease, doses of the first and control injections, complications and
expectations from the therapy collected from the medical records. The patients were divided
into two groups as under the age of 45 and age of 45 and older. These groups were compared
with each other in terms of mentioned variables.
Results: A total of 200 patients included in this study. The mean botulinum toxin dose was
33.7 units and the mean control dose was 4.5 units. Three (1.5%) of the patients developed a
complication, all of them were eyelid ptosis. Most common expectation from the toxin
injection was to look more young (69%) and vigorous (75.5%). There were no significant
difference between the under the age of 45 and 45 and older group in terms of total BTX-A
dose and control dose and complication rate (p=0.8, p=0.5, p=0.6). Expectation of looking
less angry and less saggy were significantly higher in the 45 year and older group (p=0.02,
p=0.02).
Conclusion: It is important to evaluate the patient’s gender, age and expectations from the
botulinum toxin injection to get the highest efficiency from BTX-A injection.
Funder
Destekleyen kurum bulunmamaktadır.
Publisher
Medical Journal of Ankara Training and Research Hospital
Subject
General Earth and Planetary Sciences,General Environmental Science
Reference28 articles.
1. 1.Jia Z, Lu H, Yang X, Jin X, Wu R, Zhao J, et al. Adverse Events of
Botulinum Toxin Type A in Facial Rejuvenation: A Systematic Review
and Meta-Analysis. Aesthetic Plast Surg. 2016;40(5):769-77.
2. 2.Charles FJ, Cox SE, Earl ML. Social implications of hyperfunctional
facial lines. Dermatol Surg. 2003;29(5):450-5.
3. 3.Gart MS, Gutowski KA. Overview of Botulinum Toxins for Aesthetic
Uses. Clin Plast Surg. 2016;43(3):459-71.
4. 4.American Society of Plastic Surgeons. 2018 National PlasticSurgery
Statistics; 2018. www.plast icsur gery.org/documents/News/Statistics/
2018/plastic-surge ry-stati stics-report-2018.pdf.Accessed
June 28, 2019.
5. 5.Niamtu J 3rd. Complications in fillers and Botox. Oral Maxillofac Surg
Clin North Am. 2009;21(1):13-21, v. doi: 10.1016/j.coms.2008.11.001.
PMID: 19185791.